Clinical trialNCT02088112CompletedPhase 1Interventional

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

SponsorMedImmune LLCEnrollment56Carcinoma, Non-Small-Cell Lung

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study consists of two phases: Escalation phase and an expansion phase to be conducted in locally advanced or metastatic NSCLC subjects

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ben Creelan, MD
Moffit Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Don Gibbons, MD
M.D. Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Dong-Wan Kim, MD
Seoul National University Hospital
Principal Investigator
clinicaltrials.gov ↗
Laura Chow, MD
University of Washington
Principal Investigator
clinicaltrials.gov ↗
Naoyuki Nogami
Shikoku Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Sang-We Kim, MD
Asan Medical Center
Principal Investigator
clinicaltrials.gov ↗
Shinitaro Kanda, MD
National Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Japan

Research Site
Chūōku, Japan
Research Site
Matsuyama, Japan

South Korea

Research Site
Seoul, South Korea
Research Site
Seoul, South Korea

United States

Research Site
Tampa, Florida, United States
Research Site
Houston, Texas, United States
Research Site
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gefitinib →MEDI4736

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Mar 2014
Primary completion: 9 Mar 2021
Completion: 9 Mar 2021
Last update posted: 4 Apr 2022
Registered enrollment: 56
Registry id: NCT02088112

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.